N-Power Medicine has raised $32 Million in New Series B Funding

According to filings with the U.S. Securities and Exchange Commission, N-Power Medicine has raised $32,000,000.00 in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Labcorp Venture Fund, Merck Global Health Innovation Fund (Merck GHI), Innovatus Capital Partners

About N-Power Medicine
N-Power Medicine is a clinical research and drug development platform company focused on transforming how oncology trials are conducted by building the first always on clinical research system in community oncology. Through a national network of research-ready community oncology practices, proprietary infrastructure, and embedded technology and personnel, the company integrates trial-grade, prospective data collection into routine cancer care so that every patient can participate in research, either as a trial participant or as part of a Prospective External Control Arm (ProECA). This model is designed to dramatically increase clinical trial participation, reduce or replace traditional randomized control arms, and shorten oncology drug development timelines while expanding access to innovative therapies for patients in the communities where they live. N Power Medicine positions itself at the forefront of oncology innovation by redefining trial design, de risking and accelerating R&D for biopharma partners, and leveraging its Kaleido Registry and always on ProECA platform to make trials faster, smaller, and more efficient. The company emphasizes collaboration with community oncologists and health systems to create a next generation ecosystem where clinical research is seamlessly embedded in standard care, unlocking the full potential of real world, regulatory grade data to bring life saving cancer treatments to patients sooner.

To learn more, visit https://www.npowermedicine.com/
Linkedin: https://www.linkedin.com/company/n-power-medicine-inc/

Contact:
Mark Lee, Chief Executive Officer
https://www.linkedin.com/in/mark-lee-07a8418

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.